NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea · Delayed Price · Currency is KRW 700.00
-21.00 (-2.91%)
At close: Oct 23, 2026
NGeneBio Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 41,804 | 21,240 | 5,611 | 4,351 | 11,018 | 7,163 |
Revenue Growth | 538.45% | 278.54% | 28.96% | -60.51% | 53.81% | - |
Gross Profit Gross Profit Growth | 5,783 | 3,776 | 2,049 | -153.65 | 4,128 | 2,390 |
Operating Income Operating Income Growth | -6,302 | -8,276 | -12,592 | -13,425 | -8,599 | -8,732 |
Net Income Net Income Growth | -5,041 | -5,542 | -12,976 | -12,769 | -9,785 | -8,431 |
Earnings Per Share EPS Growth | -589.18 | -741.00 | -2887.33 | -3021.00 | -2352.64 | -2046.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
South Korea South Korea Growth | 38,822 | 17,261 | 3,057 | 4,117 | 9,805 | 5,966 |
Overseas Overseas Growth | 2,982 | 3,979 | 2,554 | 233.96 | 1,213 | 1,198 |
Total Total Growth | 41,804 | 21,240 | 5,611 | 4,351 | 11,018 | 7,163 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 6,546 | 5,675 | 7,496 | 22,427 | 34,918 | 24,307 |
Total Debt Total Debt Growth | 36,387 | 33,249 | 9,019 | 11,444 | 11,456 | 7,207 |
Net Cash (Debt) Net Cash Growth | -29,842 | -27,574 | -1,523 | 10,983 | 23,462 | 17,100 |
Net Cash Growth | - | - | - | -53.19% | 37.20% | - |
Net Cash Per Share Net Cash Per Share Growth | -3476.72 | -3678.51 | -274.31 | 2597.56 | 5640.72 | 4147.91 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -5,127 | -8,482 | -12,431 | -9,167 | -7,820 | -7,523 |
Capital Expenditures CapEx Growth | -26,632 | -25,852 | -135.37 | -386.37 | -1,029 | -3,023 |
Free Cash Flow Free Cash Flow Growth | -31,759 | -34,334 | -12,566 | -9,553 | -8,849 | -10,546 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 13.83% | 17.78% | 36.52% | -3.53% | 37.47% | 33.36% |
Operating Margin | -15.08% | -38.96% | -224.42% | -308.56% | -78.05% | -121.90% |
Pretax Margin | -13.96% | -20.33% | -196.91% | -302.82% | -89.31% | -117.70% |
Profit Margin | -12.06% | -26.09% | -231.25% | -293.48% | -88.82% | -117.70% |
FCF Margin | -75.97% | -161.65% | -223.95% | -219.57% | -80.32% | -147.22% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 0.27 | 1.72 | 5.78 | 16.47 | 10.53 | 28.11 |